top of page

New USA study confirms VE wanes to ~50% after 5m, but VE vs. hospitalization remains strong at >90%

Updated: Oct 7, 2021

A paper published October 4, 2021 in The Lancet based on >3.4m USA patients found Pfizer vaccine effectiveness (VE) vs. infection decreased from 88% 1m after vaccination to 47% after 5m, but that VE vs. hospitalization remained strong at 93% through 6m.


This post will briefly summarize key results.


This paper followed >3.4m patients >12yr old in the Kaiser Permanente Southern California (KPSC) system between December 2020 and July 2021 using a retrospective cohort design.


All patients needed to have >1yr of previous data for inclusion to establish comorbidities that were used in the modeling.


Their primary analysis computed relative risk of PCR+ infection, comparing unvaccinated with fully vaccinated individuals for each calendar day using Cox regression models with vaccination status including as a time-varying covariate. This approach adjusts for any time confounding since it effectively compares the vaccinated and unvaccinated cohorts for each calendar day and aggregates information across days to arrive at the VE estimate, which is computed as:


VE = 100 x (1 - HR),


where HR is the ratio of hazard of infection for fully vaccinated and unvaccinated cohorts.


To adjust for potential confounding, in the model they adjusted for age, sex, race, previous SARS-CoV-2 infection, SES, previous health-care utilization, & various co-morbidities including BMI, acute myocardial infarction, congestive heart failure, cerebrovascular disease, peripheral vascular disease, organ transplant, diabetes, cancer, renal disease, COPD, hypertension, the Charlson comorbidity index, as well as flu vaccine in the preceding year and pneumococcal vaccine in the preceding 5 years.


It is of particular importance that they adjusted for previous SARS-CoV-2 infection, given substantial data showing that previously infected individuals still tend to have a strong level of immune protection even if unvaccinated, and if vaccinated have an even stronger level of protection than vaccinated individuals without previous infection. Studies that do not adjust for previous infection status have the potential for major bias in estimating VE.


Their results validate what has been seen in Israel, UK and elsewhere: that Pfizer VE vs. infection wanes over time, down near 50%, consistency across all age groups 16yr+

While waning, the VE vs. infection does not go down anywhere near zero, so there is still protection vs. infection. It is just that it is not as strong as it was closer to vaccination time.


This has been consistently found to be the case in papers that model VE using rigorous models trying to adjust for potential confounders, and counters the narrative that after 6m the Pfizer vaccine no longer protects vs. infection but only reduces severity of disease.


They sequenced the positive samples to evaluate the variants. We can see the shift in variants in this region, dominated by Epsilon in the winter, Alpha in the spring, and Delta in the summer.



There is some concern of confounding with variant type since Delta emerged more recently the longest after vaccination.


But looked at waning VE separately by variant, and found that the waning was not an artifact of Delta, and that the waning effect is seen across all variants.



They also analyzed Pfizer vaccine effectiveness vs. hospitalization, with cases defined as hospitalizations with positive PCR test between 14 days before admission to 3 days after admission, using a similar model.




There is no sign of any waning VE vs. hospitalized infections in any age group (see plot above for legend for which color line corresponds to which age group), remaining near 90% through 5m post vaccination. Taken together, this paper validates other data showing:


(1) VE vs. infection wanes down to ~50% after 6m

(2) VE vs. serious disease remains >90% after 6m.


These results match what was found by a study of waning VE done in Israel last month that also rigorously modeled various key confounding factors .


Note: It is disclosed that Pfizer sponsored this study and was involved in the interpretation. Thus, I encourage critical assessment of the design, analysis, and interpretation.


But from my initial reading, the study was well designed, rigorously analyzed using appropriate statistical analysis methods that account for known confounders as best as possible, and the conclusions they draw are appropriately supported by the data, with appropriate accounting for uncertainty. Thus, it appears to be a well-done study that adds to our accruing knowledge of waning vaccine effectiveness for Pfizer vaccines.


Appendix 10/7/21 -- NEJM Study on Waning Immunity from Qatar:

Another paper just came out in NEJM with further corroborating evidence for the waning of vaccine effectiveness vs. infection from a large matched case/control (vaccinated/not) test negative design study out of Qatar.


The study similarly found a sharp reduction in VE vs. infection at 5-6m after vaccination. The magnitude was greater than the USA or Israeli studies showed. This might be related to the fact that Qatar does extensive asymptomatic testing, testing every person in the country every 2 weeks regardless of symptoms, so the vast majority of detected breakthrough cases are symptomatic. We know the vaccines protect less strongly against asymptomatic than symptomatic disease, especially over time as the waning effect is much stronger in asymptomatic disease.


Also, the Qatari population demographics is very different than most other countries -- nearly all younger people and from all over the world -- with only 1-2% over age 65. These dynamics can strongly affect the risk of exposure, especially with certain travel and other privileges only available to vaccinated individuals. The Qatari study looks very well designed, and provides an important complementary perspective on vaccine effectiveness over time in a different population demographic and in a setting with extensive asymptomatic testing.


On the positive side, as we have seen in other studies, even with this sharp decline in VE vs. infection at 5-6m, the VE vs. serious/hospitalized/fatal disease remains much more durable over time, remaining near 90% even at these time points.

3,408 views67 comments

Recent Posts

See All

Explanation of "Healthy Vaccinee Effect" and Confounding

Healthy vaccinee effect (HVE) has become frequent topic of discussion these days. I am glad to see this, as I have been talking about this phenomenon for the past 2.5 years, and for a long time no one

67 Comments


The study measures protection against infection by PCR tests regardless of symptoms. Unvaccinated test far more due to legal requirements, and I assume that KP will also test all unvaccinated people admitted to the hospital for any reason, while they only test vaccinated if they are symptomatic. This badly skews the evaluation of protection against infection, to the point that the data is meaningless. The measure for hospitalization also depends on a PCR test with hospitalization for any reason, so this data is also not worth anything for the same reason.


What would have been valuable is looking at the rate of positive PCR tests for symptomatic individuals by vaccination status as a measure of protection against infection, and the CFR…


Like

On the subject of indefinite boosters. It is quite likely that COVID will end up like Flu, where everyone has some immunity from prior infection and vaccination enhances this, particularly important for older people but helpful for all. The arguments for boosters would be similar to those for/against Flu jabs.


Where we do need careful analysis is on how often such boosters are needed. Perhaps protection from COVID vaccines will persist better than against Flu. In addition, it is likely that mutation of COVID as an endemic disease will be lower than Flu. So there is room to be optimistic it might be COVID jabs every two years not one. That is speculation, we do not have enough data to…


Like

I would like to bring to your attention twin studies done by public health agencies in B.C. and Quebec in Canada.


As background, due to vaccine shortages in Canada in the spring, the National Advisory Committee on Immunization recommended that the second dose be delayed by up to 16 weeks in order to maximize the number of people who could receive a first dose. They also authorized mixed vaccines, any combination of AZ, Moderna or Pfizer.


The public health agency studies, which are in pre-print, are showing that the delay in dosing has maintained the level of vaccine effectiveness, both for infection and severe disease, after 4 months and that there is currently no indication of waning immunity.


"Deepta Bhattacharya,…


Like
Replying to

Several countries, including the USA have approved the administration of mixed vaccines.


The FDA just recently approved the mixed vaccine approach for boosters, approving any combination of J&J and mRNA vaccines.


During the initial vaccine rollout numerous countries (Canada, France, Germany, Spain, etc) approved the use of mixed vaccines. This was done for various reasons but was based on an understanding of how vaccines work and previous experience with mixing vaccines.


https://www.npr.org/2021/05/05/993754404/experts-weigh-in-on-mixing-and-matching-covid-19-vaccines


Also, during the vaccine rollout numerous countries were faced with bumps in the road. Countries that began using the AZ vaccine decided to suspend its use when the rare clot side effect became known. This left millions of people with only one dose of vaccine. At the same…


Like

"Qatar does extensive asymptomatic testing, testing every person in the country every 2 weeks regardless of symptoms, so the vast majority of detected breakthrough cases are symptomatic." Should read "asymptomatic ;)

Like

Prof Morris,


There has been a wall of protection erected around the vaccine industry like no other in history. They have no direct financial liability or direct accountability for the individual damage they cause; they only fear fines that may be levied by regulators.


They are completely unaccountable to their victims - and there have been many of these. In very recent history, Purdue Pharma is alleged to have murdered at least 500,000 Americans with just a single product, as one example.


Insiders have written books about alleged mob-like activities of the industry. Is it not justified for the public to be just a little bit sceptical of anything put forward by this industry?


Here we have a Pfizer study…


Like
Jeffrey Morris
Jeffrey Morris
Oct 08, 2021
Replying to

This paper has undergone peer review.


I understand people's concerns about lack of legal liability for vaccines for the past 35+ years, and also people's skepticism about pharmaceutical involvement in scientific papers. But I see no evidence of any data manipulation or improper analyses, and the source of data is clearly stated to be from a specific health systems EMR.


Of course we don't see the raw data but I see no reason to make a blanket assumption that data are fake because a pharmaceutical company was involved in the study.


I choose to evaluate papers on their merits -- I believe it is reasonable to have skepticism from such things but that it is not appropriate to be automatically…

Like
Post: Blog2_Post
bottom of page